Summary
Check out our latest interview with SOPHiA GENETICS, a company revolutionizing healthcare by leveraging data-driven technology to improve the diagnosis and treatment of cancer and rare diseases. In this conversation with Paul Chilo, Director of Governance, Risk & Compliance, we explore UNITY, a global oncology platform, and discuss the compliance strategy behind this international initiative, as well as our collaboration in making it a reality.
Here is the latest interview with one of our clients - SOPHiA GENETICS,. SOPHiA GENETICS was founded in 2011 by biologists who saw an opportunity to address the growing need for answers to diseases of the DNA.
They believed technology could make a positive and lasting impact on the world, using data for good.Their vision was to build a future in which each patient has equal access to world-class care, and today, they are well underway to realizing that impact. SOPHia has built a technology platform that distills complex data into actionable insights to reshape the way that cancer and rare inherited disorders are diagnosed and treated.
In this interview with Paul Chilo, Director of Governance, Risk & Compliance at SOPHiA GENETICS, we explore the latest initiative, UNITY, a global oncology platform. We discuss SOPHiA GENETICS’ compliance strategy for this international project, as well as our collaboration and partnership in bringing it to life.
FAQs
Our frequently questions
Find out how iliomad can help your company.
Only visible in production
Healthcare AI Agents, Vendor Breaches and GDPR Reforms: Weekly Privacy and Regulation Digest
This week's digest covers autonomous AI agent risks, a wave of US healthcare vendor breaches, the EU Digital Omnibus GDPR mandate and Swiss voice-biometric enforcement.
Clinical study protocol data protection: a practical guide for sponsors
Learn how to embed GDPR-compliant data protection into your clinical study protocol. Practical guidance on Section 13, DPIAs, transfers and local formalities.
Clinical Site Agreement: Navigating US Export Control Review of Cross-Border Data Transfers in Clinical Trials
Learn how institutional export control policies at clinical sites affect cross-border data transfers in trials, even below DOJ Bulk Data Rule thresholds.
